Inventor · disambiguated record
Curtis Harwig
Also filed as: HARWIG CURTIS
32 granted patents·17 pending applications·434 citations·filing 2000–2023
97Inventor score
Files withAQUINOX PHARMACEUTICALS CANADA INC13GENZYME CORP12ANORMED INC9TARO PHARMACEUTICALS INC6BRIDGER GARY3
Top patents by PatentIndex Score
49 records- 0196US7863293B2CXCR4 chemokine receptor binding compoundsGENZYME CORP·Filed 2007·Granted Jan 4, 2011·24 cites·18 claims
- 0295US7291631B2CXCR4 chemokine receptor binding compoundsGENZYME CORP·Filed 2004·Granted Nov 6, 2007·50 cites·25 claims
- 0394US7354934B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2005·Granted Apr 8, 2008·34 cites·10 claims
- 0494US6864265B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted Mar 8, 2005·42 cites·6 claims
- 0594US6750348B1Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2000·Granted Jun 15, 2004·61 cites·30 claims
- 0693US7091217B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2004·Granted Aug 15, 2006·31 cites·12 claims
- 0793US6835731B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted Dec 28, 2004·53 cites·10 claims
- 0893US6734191B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted May 11, 2004·35 cites·15 claims
- 0990US7354932B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2003·Granted Apr 8, 2008·27 cites·21 claims
- 1089US8778967B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2012·Granted Jul 15, 2014·18 cites·20 claims
- 1188US9765085B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS (CANADA) INC·Filed 2014·Granted Sep 19, 2017·12 cites·8 claims
- 1284US7550484B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2004·Granted Jun 23, 2009·19 cites·11 claims
- 1382US9540353B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS (CANADA) INC·Filed 2014·Granted Jan 10, 2017·6 cites·19 claims
- 1479US11352367B2Indene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·2 cites·38 claims
- 1576US7396840B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Jul 8, 2008·1 cites·9 claims
- 1675US10322111B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2016·Granted Jun 18, 2019·1 cites·13 claims
- 1775US7312234B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Dec 25, 2007·7 cites·6 claims
- 1873US7629337B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Dec 8, 2009·1 cites·9 claims
- 1972US2023391790A1Indene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2070US10100056B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2014·Granted Oct 16, 2018·1 cites·7 claims
- 2169US7084155B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Aug 1, 2006·3 cites·15 claims
- 2268US11773108B2Indene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2022·Granted Oct 3, 2023·0 cites·18 claims
- 2367US7183273B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2004·Granted Feb 27, 2007·2 cites·10 claims
- 2467US2020000774A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2019·Application pending·0 cites
- 2566US8101605B2SHIP1 modulators and methods related theretoMACKENZIE LLOYD·Filed 2010·Granted Jan 24, 2012·4 cites·17 claims
- 2663US2015038509A1Chemokine Receptor Binding Heterocyclic Compounds With Enhanced EfficacyGENZYME CORP·Filed 2014·Application pending·0 cites
- 2762US7807694B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Oct 5, 2010·0 cites·4 claims
- 2862US2008167341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2008·Application pending·0 cites
- 2961US2010105915A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY J·Filed 2009·Application pending·0 cites
- 3061US2023002366A1Indene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3160US10065920B2Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(aminomethyl)-7A-methyl-1-methyleneoctahydro-1H-inden-5-YL)-3- (hydroxymethyl)-4-methylcyclohexanolAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Granted Sep 4, 2018·0 cites·5 claims
- 3260US2023203089A1Hexadecahydro-1h-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3359US2009281308A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY J·Filed 2009·Application pending·0 cites
- 3459US2022409589A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2022·Application pending·0 cites
- 3558US2021024571A1Hexadecahydro-1h-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammationAQUINOX PHARMACEUTICALS CANADA INC·Filed 2019·Application pending·0 cites
- 3657US2008090846A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY·Filed 2007·Application pending·0 cites
- 3756US9944590B2Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanolAQUINOX PHARMACEUTICALS CANADA INC·Filed 2016·Granted Apr 17, 2018·0 cites·7 claims
- 3855US2018290964A1Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanolAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Application pending·0 cites
- 3953US11420962B2Indene derivatives useful in treating pain and inflammationTARO PHARMACEUTICALS INC·Filed 2019·Granted Aug 23, 2022·0 cites·58 claims
- 4053US10272081B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Granted Apr 30, 2019·0 cites·2 claims
- 4152US7790747B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2006·Granted Sep 7, 2010·0 cites·14 claims
- 4251US2019023709A1Ship1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Application pending·0 cites
- 4350US9937167B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2016·Granted Apr 10, 2018·0 cites·20 claims
- 4449US10174046B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2017·Granted Jan 8, 2019·0 cites·11 claims
- 4549US2003220341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyFiled 2002·Application pending·0 cites
- 4644US2007066624A1Chemokine receptor binding compoundsANORMED INC·Filed 2006·Application pending·0 cites
- 4743US2010298366A1Chemokine receptor binding compoundsGENZYME CORP·Filed 2010·Application pending·0 cites
- 4840US10053415B2Synthesis of a substituted indene derivativeAQUINOX PHARMACEUTICALS CANADA INC·Filed 2017·Granted Aug 21, 2018·0 cites·42 claims
- 4938US2018085460A1Methods of treating prostatitisAQUINOX PHARMACEUTICALS CANADA INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Curtis Harwig files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →